Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis

Journal of the Formosan Medical Association

Volumn 111, Issue 11, 2012, Pages 589-598

  Chang, Fan Chi ^a,b   Chou, Yu Hsiang ^a   Chen, Yi Ting ^a,b   Lin, Shuei Liong ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Endothelial cell; Macrophage; Myofibroblast; Pericyte; Renal fibrosis

Indexed keywords

ANGIOGENIC FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CAPILLARY BASEMENT MEMBRANE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENDOTHELIUM CELL; INTERSTITIUM; KIDNEY FIBROSIS; MACROPHAGE ACTIVATION; MOLECULAR INTERACTION; MOUSE; MYOFIBROBLAST; NONHUMAN; PERICYTE; REVIEW; SIGNAL TRANSDUCTION; UREMIA;

CELL MOVEMENT; ENDOTHELIAL CELLS; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MACROPHAGE ACTIVATION; MYOFIBROBLASTS; PERICYTES; SIGNAL TRANSDUCTION;

EID: 84872420242     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2012.09.008     Document Type: Review

References (98)

1. Lin S.L., Li B., Rao S., Yeo E.J., Hudson T.E., Nowlin B.T., et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci U S A 2010, 107:4194-4199.
2. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007, 117:524-529.
3. Rojas A., Chang F.C., Lin S.L., Duffield J.S. The role played by perivascular cells in kidney interstitial injury. Clin Nephrol 2012, 77:400-408.
4. Schrimpf C., Xin C., Campanholle G., Gill S.E., Stallcup W., Lin S.L., et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol 2012, 23:868-883.
5. Schrimpf C., Duffield J.S. Mechanisms of fibrosis: the role of the pericyte. Curr Opin Nephrol Hypertens 2011, 20:297-305.
6. Hirschberg R. Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. J Am Soc Nephrol 2005, 16:9-11.
7. Lin S.L., Duffield J.S. Macrophages in kidney injury and repair. Acta Nephrol 2012, 26:45-57.
8. Lin S.L., Castano A.P., Nowlin B.T., Lupher M.L., Duffield J.S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009, 183:6733-6743.
9. Castano A.P., Lin S.L., Surowy T., Nowlin B.T., Turlapati S.A., Patel T., et al. Serum amyloid P inhibits fibrosis through FcγR dependent monocyte/macrophage regulation in vivo. Sci Transl Med 2009, 1:5ra13.
10. Darby I., Skalli O., Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 1990, 63:21-29.
11. Lin S.L., Kisseleva T., Brenner D.A., Duffield J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173:1617-1627.
12. Ebralidze A., Tulchinsky E., Grigorian M., Afanasyeva A., Senin V., Revazova E., et al. Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes Dev 1989, 3:1086-1093.
13. Inoue T., Plieth D., Venkov C.D., Xu C., Neilson E.G. Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int 2005, 67:2488-2493.
14. Hobbs J.A., May R., Tanousis K., McNeill E., Mathies M., Gebhardt C., et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003, 23:2564-2576.
15. Takenaga K., Nakamura Y., Sakiyama S. Expression of a calcium binding protein pEL98 (mts1) during differentiation of human promyelocytic leukemia HL-60 cells. Biochem Biophys Res Commun 1994, 202:94-101.
16. Klingelhofer J., Ambartsumian N.S., Lukanidin E.M. Expression of the metastasis-associated mts1 gene during mouse development. Dev Dyn 1997, 210:87-95.
17. Grigorian M., Tulchinsky E., Burrone O., Tarabykina S., Georgiev G., Lukanidin E. Modulation of mts1 expression in mouse and human normal and tumor cells. Electrophoresis 1994, 15:463-468.
18. Hume D.A., Ross I.L., Himes S.R., Sasmono R.T., Wells C.A., Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol 2002, 72:621-627.
19. Boor P., Ostendorf T., Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010, 6:643-656.
20. Eddy A.A. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005, 12:353-365.
21. Fan J.M., Ng Y.Y., Hill P.A., Nikolic-Paterson D.J., Mu W., Atkins R.C., et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999, 56:1455-1467.
22. Johnson R.J., Floege J., Yoshimura A., Iida H., Couser W.G., Alpers C.E. The activated mesangial cell: a glomerular " myofibroblast" ?. J Am Soc Nephrol 1992, 2:S190-S197.
23. Gressner A.M. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl 1996, 54:S39-S45.
24. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
25. Ng Y.Y., Huang T.P., Yang W.C., Chen Z.P., Yang A.H., Mu W., et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998, 54:864-876.
26. Iwano M., Fischer A., Okada H., Plieth D., Xue C., Danoff T.M., et al. Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther 2001, 3:149-159.
27. Duffield J.S., Tipping P.G., Kipari T., Cailhier J.F., Clay S., Lang R., et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005, 167:1207-1219.
28. Humphreys B.D., Lin S.L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97.
29. Koesters R., Kaissling B., Lehir M., Picard N., Theilig F., Gebhardt R., et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010, 177:632-643.
30. Bielesz B., Sirin Y., Si H., Niranjan T., Gruenwald A., Ahn S., et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010, 120:4040-4054.
31. Forbes S.J., Russo F.P., Rey V., Burra P., Rugge M., Wright N.A., et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004, 126:955-963.
32. Roufosse C., Bou-Gharios G., Prodromidi E., Alexakis C., Jeffery R., Khan S., et al. Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J Am Soc Nephrol 2006, 17:775-782.
33. Lin F., Moran A., Igarashi P. Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest 2005, 115:1756-1764.
34. Duffield J.S., Bonventre J.V. Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int 2005, 68:1956-1961.
35. Direkze N.C., Forbes S.J., Brittan M., Hunt T., Jeffery R., Preston S.L., et al. Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells 2003, 21:514-520.
36. Duffield J.S., Park K.M., Hsiao L.L., Kelley V.R., Scadden D.T., Ichimura T., et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest 2005, 115:1743-1755.
37. Lin S.L., Chang F.C., Schrimpf C., Chen Y.T., Wu C.F., Wu V.C., et al. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011, 178:911-923.
38. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005, 97:512-523.
39. Chen Y.T., Chang F.C., Wu C.F., Chou Y.H., Hsu H.L., Chiang W.C., et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 2011, 80:1170-1181.
40. Duffield J.S., Humphreys B.D. Origin of new cells in the adult kidney: results from genetic labeling techniques. Kidney Int 2011, 79:494-501.
41. Ozerdem U., Monosov E., Stallcup W.B. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res 2002, 63:129-134.
42. Picard N., Baum O., Vogetseder A., Kaissling B., Le Hir M. Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem Cell Biol 2008, 130:141-155.
43. Goritz C., Dias D.O., Tomilin N., Barbacid M., Shupliakov O., Frisen J. A pericyte origin of spinal cord scar tissue. Science 2011, 333:238-242.
44. Sato M., Suzuki S., Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003, 28:105-112.
45. Suematsu M., Aiso S. Professor Toshio Ito: a clairvoyant in pericyte biology. Keio J Med 2001, 50:66-71.
46. Sponheim J., Pollheimer J., Olsen T., Balogh J., Hammarstrom C., Loos T., et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol 2010, 177:2804-2815.
47. Kisseleva T., Cong M., Paik Y., Scholten D., Jiang C., Benner C., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012, 109:9448-9453.
48. Faulkner J.L., Szcykalski L.M., Springer F., Barnes J.L. Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis. Am J Pathol 2005, 167:1193-1205.
49. Asada N., Takase M., Nakamura J., Oguchi A., Asada M., Suzuki N., et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011, 121:3981-3990.
50. Rao S., Lobov I.B., Vallance J.E., Tsujikawa K., Shiojima I., Akunuru S., et al. Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development (Cambridge, England) 2007, 134:4449-4458.
51. Uemura A., Ogawa M., Hirashima M., Fujiwara T., Koyama S., Takagi H., et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 2002, 110:1619-1628.
52. Evensen L., Micklem D.R., Blois A., Berge S.V., Aarsaether N., Littlewood-Evans A., et al. Mural cell associated VEGF is required for organotypic vessel formation. PloS One 2009, 4:e5798.
53. Darland D.C., Massingham L.J., Smith S.R., Piek E., Saint-Geniez M., D'Amore P.A. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003, 264:275-288.
54. Visconti R.P., Richardson C.D., Sato T.N. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 2002, 99:8219-8224.
55. Strutz F., Zeisberg M., Hemmerlein B., Sattler B., Hummel K., Becker V., et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 2000, 57:1521-1538.
56. Zhang J., Cao R., Zhang Y., Jia T., Cao Y., Wahlberg E. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J 2009, 23:153-163.
57. Kuhnert F., Tam B.Y., Sennino B., Gray J.T., Yuan J., Jocson A., et al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci U S A 2008, 105:10185-10190.
58. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
59. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellstrom M., et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003, 17:1835-1840.
60. Jonsson-Rylander A.C., Nilsson T., Fritsche-Danielson R., Hammarstrom A., Behrendt M., Andersson J.O., et al. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler Thromb Vasc Biol 2005, 25:180-185.
61. Vazquez F., Hastings G., Ortega M.A., Lane T.F., Oikemus S., Lombardo M., et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999, 274:23349-23357.
62. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003, 9:407-415.
63. Saunders W.B., Bohnsack B.L., Faske J.B., Anthis N.J., Bayless K.J., Hirschi K.K., et al. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 2006, 175:179-191.
64. Gill S.E., Huizar I., Bench E.M., Sussman S.W., Wang Y., Khokha R., et al. Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am J Pathol 2010, 176:64-73.
65. Ohashi R., Shimizu A., Masuda Y., Kitamura H., Ishizaki M., Sugisaki Y., et al. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 2002, 13:1795-1805.
66. Grunstein J., Masbad J.J., Hickey R., Giordano F., Johnson R.S. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol 2000, 20:7282-7291.
67. Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouche A., Yuce A., et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002, 109:327-336.
68. Lobov I.B., Rao S., Carroll T.J., Vallance J.E., Ito M., Ondr J.K., et al. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature 2005, 437:417-421.
69. Lin S.L., Ichimura T., Nathans J., Lang R., Duffield J.S. Frizzled receptors 4 and 7 mediate the activation of Wnt/β-catenin pathway by macrophages in kidneys of unilateral ureteral obstruction. J Am Soc Nephrol 2007, 18:8A.
70. Hakroush S., Moeller M.J., Theilig F., Kaissling B., Sijmonsma T.P., Jugold M., et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol 2009, 175:1883-1895.
71. Mallamaci F., Benedetto F.A., Tripepi G., Cutrupi S., Pizzini P., Stancanelli B., et al. Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. J Hypertens 2008, 26:1875-1882.
72. Kim I., Moon S.O., Kim S.H., Kim H.J., Koh Y.S., Koh G.Y. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001, 276:7614-7620.
73. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
74. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 115:56-65.
75. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993, 122:103-111.
76. Roy S.G., Nozaki Y., Phan S.H. Regulation of [alpha]-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int J Biochem Cell Biol 2001, 33:723-734.
77. Dickson M.C., Martin J.S., Cousins F.M., Kulkarni A.B., Karlsson S., Akhurst R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995, 121:1845-1854.
78. Larsson J., Goumans M.J., Sjostrand L.J., van Rooijen M.A., Ward D., Leveen P., et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J 2001, 20:1663-1673.
79. Oshima M., Oshima H., Taketo M.M. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996, 179:297-302.
80. El Chaar M., Chen J., Seshan S.V., Jha S., Richardson I., Ledbetter S.R., et al. Effect of combination therapy with enalapril and the TGF-beta antagonist 1D11 in unilateral ureteral obstruction. Am J Physiol Renal Physiol 2007, 292:F1291-F1301.
81. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494.
82. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Noncanonical TGF-{beta} pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010, 298:F142-F149.
83. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 2005, 19:1-11.
84. Chevalier R.L. Specific molecular targeting of renal injury in obstructive nephropathy. Kidney Int 2006, 70:1200-1201.
85. Docherty N.G., O'Sullivan O.E., Healy D.A., Fitzpatrick J.M., Watson R.W. Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol 2006, 290:F4-13.
86. Patel V., Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012, 21:410-416.
87. Lan H.Y., Chung A.C. Transforming growth factor-beta and Smads. Contrib Nephrol 2011, 170:75-82.
88. Chau B.N., Xin C., Hartner J., Ren S., Castano A.P., Linn G., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012, 4:121ra18.
89. Chang FC, Lai TS, Chiang CK, Hung KY, Chen YM, Wu MS, et al. Angiopoietin-2 is associated with malnutrition, inflammation, and albuminuria in chronic kidney disease. PLoS One. submitted for publication.
90. Wasada T., Kawahara R., Katsumori K., Naruse M., Omori Y. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998, 47:27-30.
91. Harper S.J., Downs L., Tomson C.R., Dwight J.S., Bolton C. Elevated plasma vascular endothelial growth factor levels in non-diabetic predialysis uraemia. Nephron 2002, 90:341-343.
92. Stompor T., Zdzienicka A., Motyka M., Dembinska-Kiec A., Davies S.J., Sulowicz W. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int 2002, 22:670-676.
93. Eardley K.S., Kubal C., Zehnder D., Quinkler M., Lepenies J., Savage C.O., et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008, 74:495-504.
94. de Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001, 12:993-1000.
95. Ostendorf T., Kunter U., Eitner F., Loos A., Regele H., Kerjaschki D., et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999, 104:913-923.
96. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
97. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707-716.
98. Duffield J.S., Lupher M.L. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect 2010, 235:305-315.